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The p53 tumor suppressor is stabilized in cells expressing the human papillomavirus type 16 (HPV-16) E7 oncoprotein. In
contrast, expression of the HPV-16 E6 protein inactivates p53 by targeting it for proteasomal degradation. Since p53
activation is associated with protein accumulation we investigated the biochemical mechanisms and biological conse-
quences of p53 stabilization in HPV-16 E7-expressing cells. Transcriptional reporter assays, expression profiling studies
using cDNA arrays, and immunoblot analyses of known p53 target genes suggest that p53 remains transcriptionally inert in
E7-expressing cells. The stabilized p53 in E7-expressing cells is in a wild-type conformation and the same number of
phospho-forms is present. Furthermore, E7 expression does not alter p53 localization or generally block nuclear export or
proteasomal degradation of p53. Moreover, the stabilized p53 remains susceptible to mdm2-induced proteasome-mediated
degradation, and exogenous transfected p53 is transcriptionally active in E7-expressing cells. Taken together, these resultsINTRODUCTION
Human papillomaviruses (HPVs) are small DNA vi-
ruses that infect epithelial cells. More than 100 different
HPV types have been described. The mucosal-associ-
ated HPVs are classified into two groups: Low-risk HPVs
are found in benign hyperplasias with a low potential for
malignant progression, whereas high-risk HPVs are as-
sociated with squamous intraepithelial lesions that have
a propensity to progress to invasive squamous cell car-
cinoma (reviewed in Lowy and Howley, 2001). High-risk
HPVs have been etiologically linked to more than 95% of
all cervical cancers (reviewed in zur Hausen, 1996) and
approximately 20% of oral cancers; in particular, oropha-
ryngeal carcinomas are also associated with high-risk
HPV infections (Gillison et al., 2000). During carcinogenic
progression of a high-risk HPV-infected cell the viral
genome frequently integrates into a host chromosome.
This event is quite random with respect to the host
chromosome but follows a specific pattern with respect
to the viral genome. As a consequence of integration,
expression of the E6 and E7 genes is dysregulated due
to the frequent disruption of the viral E2 transcription
factor. The E6 and E7 genes of the high-risk HPVs have
oncogenic activities. E7 functionally inactivates the reti-
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74noblastoma tumor suppressor protein (pRB) and the re-
lated “pocket proteins” p107 and p130 by destabilization
(reviewed in Munger et al., 2001). The E6 protein binds to
(Werness et al., 1990) and promotes the degradation of
the tumor suppressor p53 (Scheffner et al., 1990). Expres-
sion of high-risk HPV E6 and E7 results in the extension
of the life span and immortalization of normal human
genital epithelial cells, the normal host cell type of these
viruses (Mu¨nger et al., 1989; Hawley-Nelson et al., 1989).
Moreover, continuous expression of E6 and E7 in cervi-
cal cancer cell lines is required for the maintenance of
the transformed state (Goodwin and DiMaio, 2000; Wells
et al., 2000).
Human keratinocytes or fibroblasts that express HPV-16
E7 contain elevated levels of the p53 tumor suppressor
protein (Demers et al., 1994b; Jones et al., 1997b; Thomas
and Laimins, 1998). This increase is not due to increased
transcription of p53, but results from an extension of its
half-life (Jones and Mu¨nger, 1997). In normal cells, the p53
tumor suppressor has a short half-life as it is rapidly turned
over through ubiquitin-mediated proteasomal degradation.
The p53-responsive mdm2 protein (Barak et al., 1993) inter-
acts with p53 (Momand et al., 1992) and functions as a
ubiquitin ligase (E3) in this process (Honda et al., 1997).
Upon various situations of cellular stress including DNA
damage, p53 becomes resistant to mdm2-mediated degra-
dation presumably through specific phosphorylation of
serine/threonine residues mainly in the amino-terminalsuggest that E7 can interfere with the normal turnover o
transcriptional consequences on the p53 targets that we in
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transactivation domain of the protein and is stabilized. In
addition, p53 may become acetylated at the carboxyl-termi-f p53
vestig
m on
nus. These modifications lead to stimulation of its specific
DNA-binding activity (reviewed in Meek, 1999). Similarly,
signals that cause aberrant cell cycle progression such as
E2F or the oncoproteins c-myc and adenovirus E1A stabi-
lize p53. In this case mdm2-mediated p53 degradation is
abrogated by increased expression of p14ARF (Zindy et al.,
1998; de Stanchina et al., 1998), which directly inhibits
mdm2 (Stott et al., 1998). The stabilized and activated p53
causes cells to undergo growth arrest or apoptosis
by modulating expression of specific target genes like
p21CIP1/waf1, bax, and mdm2 (reviewed in Ryan et al., 2001).
Previous studies indicate that in E7-expressing IMR90
human diploid lung fibroblasts p53 is activated upon
DNA damage to a comparable extent as in control cells
(Jones et al., 1999). This indicates that the p53 in E7-
expressing cells retains the ability to be functionally
activated upon specific stimuli. It was not clear, however,
whether the stabilized p53 in E7-expressing cells repre-
sents a transcriptionally active pool in the absence of
additional stimuli such as DNA damage. It was recently
reported that mdm2 transcription was increased through
the p53-responsive P2 promoter in E7-expressing normal
human fibroblasts (Seavey et al., 1999), thereby suggest-
ing that p53 is transcriptionally activated in E7-express-
ing cells. However, our own previous studies show that
mRNA levels of p21CIP1/waf1, a major transcriptional target
of p53, are not significantly increased in E7-expressing
IMR90 cells (Jones et al., 1999).
Here we used reporter gene assays, transcriptional
profiling using cDNA arrays, and immunoblot analyses of
known p53 target genes, to show that E7-mediated p53
stabilization does not induce a concomitant enhance-
ment of p53 transcriptional activity. To determine the
mechanisms of E7-mediated p53 stabilization, we inves-
tigated p53 phosphorylation, nuclear export, and protea-
somal degradation in E7-expressing cells. We did not
detect changes in the number of p53 phospho-forms
using two-dimensional gel electrophoresis, and immuno-
precipitations with conformation-specific antibodies re-
vealed that the stabilized p53 in E7-expressing cells is
present in a wild-type conformation. Treatment with
geldanamycin does not induce p53 destabilization, sug-
gesting that it is not bound to hsp90. Moreover, the
stabilized and transcriptionally inactive p53 in E7-ex-
pressing IMR90 cells is nuclear and remains bound to
mdm2. Interestingly, however, ectopic expression of E6
or mdm2 decreased p53 levels in E7-expressing cells,
and similarly the transcriptional activity of exogenous
p53 is not impaired by E7.
RESULTS
The stabilized p53 in HPV-16 E7-expressing cells is
transcriptionally impotent
It was reported previously that overexpression of the
HPV-16 E7 oncogene results in the accumulation (Dem-
ers et al., 1994b) and increased half-life of p53 (Jones et
al., 1997a,b) protein. To further analyze E7-mediated p53
stabilization we generated stable control and HPV-16
E7-expressing IMR90 human diploid lung fibroblasts. In
agreement with our previous studies (Jones and Mu¨nger,
1997) the p53 steady state levels were consistently three
to four times higher in E7-expressing IMR90 cells than in
control cells (Fig. 1A, 0-h time points) and the half-life of
p53 was extended in stable E7-expressing cells (Fig. 1A).
Note that the decrease of p53 levels in both LX and E7
cells is greater between the 0- and 1-h time points than
at subsequent times, suggesting that these cells may
contain two p53 populations with different half-lives.
There is conflicting evidence concerning the transcrip-
tional activity of the stabilized p53 in E7-expressing cells.
Our own study demonstrated that transcription of
p21CIP1/waf1, a major transcriptional target of p53, was not
significantly altered in E7-expressing cells (Jones et al.,
1999). Consistent with this finding it was also reported
that E7 can dampen expression of p53-responsive re-
porter plasmids in transient assays (Massimi and Banks,
1997). In contrast, another study showed that stable
HPV-16 E7-expressing fibroblasts contained elevated
mdm2 mRNA levels derived from the p53-responsive P2
promoter (Seavey et al., 1999), suggesting that p53 may
be transcriptionally active in E7-expressing cells. To fur-
ther investigate the transcriptional activity of p53 in E7-
expressing cells, we performed expression profiling us-
ing a cDNA array. The array contained a total of 12 known
p53-responsive genes. The basal level of expression of
the p53-responsive genes was variable, but none of
these genes was expressed at a significantly higher
level in E7-expressing cells (Fig. 1B). As expected from
earlier studies (Cheng et al., 1995), expression of PCNA
was higher in E7-expressing cells than in control cells
(Fig. 1B).
To more directly determine the transcriptional activity
of p53, we transfected control and E7-expressing IMR90
cells with a constant amount of firefly luciferase reporter
plasmid under the control of an artificial p53-responsive
promoter consisting of 17 p53-binding sites (pRGC-luc).
Activity was determined and normalized against the ex-
pression of the non-p53-responsive renilla luciferase re-
porter pRL-TK that was cotransfected as a transfection
control. Expression of the p53-responsive reporter con-
struct was decreased in E7-expressing cells to a level
that was approximately 40% of that of control cells (Fig.
1C) even though this E7-expressing cell population con-
tains 3.6-fold higher p53 levels than control cells (Fig. 1D,
top). Activity of the renilla luciferase reporter was not
affected by E7 expression (data not shown).
We also determined the protein levels of some p53
target genes on the cDNA array by immunoblot analysis
(Fig. 1D). Steady state levels of the pro-apoptotic p53
target genes bax (Miyashita and Reed, 1995) and DR5
(alias TRAIL-R2/Apo2/Killer) (Wu et al., 1997) were only
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slightly increased or were unchanged, respectively (Fig.
1D). Increased levels of p21CIP1/waf1 have been observed in
E7-expressing cells and are a consequence of increased
protein stability (Jones et al., 1997a) and there is no
comparable increase in mRNA levels (Fig. 1B). Taken
together these results indicate that p53 stabilization in
E7-expressing cells does not lead to a concomitant in-
crease in transcriptional activity.
No significant changes in the number of p53
phospho-forms in E7-expressing cells
In normal cells p53 is maintained at low levels primarily
through mdm2-mediated ubiquitination and proteasomal
degradation (Haupt et al., 1997; Kubbutat et al., 1997). How-
ever, various forms of cellular stress result in stabilization
and accumulation of the p53 protein as a consequence of
posttranslational modifications. Changes in p53 phosphor-
ylation status have been implicated in both stabilization and
activation of the protein (reviewed in Stewart and Pietenpol,
2001). To determine if increased p53 levels in HPV-16 E7
cells were associated with changes in p53 phosphorylation
we performed two-dimensional gel electrophoresis. To ad-
just for the different p53 levels in the two cell lines, 1 mg of
protein lysate from control cells and 250 g protein from
E7-expressing IMR90 cells were analyzed (Fig. 1E). A re-
combinant carboxyl-terminal truncated human p53 protein
(amino acids 1–353) was added to the isoelectric focusing
(IEF) sample buffer to serve as an internal standard for
alignment of the indicated phospho-forms (Stewart et al.,
2001). Although several phosphorylated p53 species were
detected, with the exception of the most highly phosphor-
ylated isoform, a significant difference in p53 phosphoryla-
tion was not observed between the control and E7-express-
ing cells.
FIG. 1. Biochemical and functional characterization of p53 in control (LX) and HPV-16 E7-expressing (E7) IMR90 cells. (A) Estimation of p53 half-life.
Cultures were treated with cycloheximide (CHX) for the indicated periods of time and 100 g aliquots of protein lysates were analyzed by SDS–PAGE
and immunoblotting. Quantification was performed after normalization for -actin expression and is shown at the bottom. (B) Expression analysis of
a set of p53 responsive genes by transcriptional profiling. A “Human Apoptosis ATLAS” cDNA nylon array (Clontech) was analyzed by sequential
hybridization with 32P-labeled single-stranded cDNA probes. PCNA is a known E7-responsive gene and was used as a positive control. (C) Decreased
transcriptional activity of the stabilized p53 in E7-expressing IMR90 cells. Cells were transfected with the artificial p53-responsive firefly luciferase
reporter plasmid pRGC-luc. Activity values were normalized for expression of a nonresponsive renilla luciferase reporter. Values represent averages
and standard deviations of an experiment performed in triplicate. (D) Immunoblot analysis of p53, and the p53 transcriptional targets p21CIP1/waf1 (p21),
bax, and DR5 (alias TRAIL-R2/Apo2/Killer). Expression of HPV-16 E7 is also shown. Relative expression levels of each protein were determined after
correction for GAPDH and are indicated below the panels in arbitrary units. (E) Two-dimensional SDS–PAGE analysis of p53. Aliquots containing
similar amounts of p53 (1 mg LX; 250 g E7) were analyzed. P0 denotes unphosphorylated p53. See text for details.
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p53 is bound to mdm2 in HPV-16 E7-expressing cells
It has been reported previously that E7-expressing
cells contain higher mdm2 levels (Thomas and Laimins,
1998; Seavey et al., 1999). In our cells steady state levels
of mdm2 mRNA and protein in control and E7-expressing
cells were too low to detect by transcriptional profiling
(Fig. 1B) or direct immunoblot analysis (data not shown),
respectively. Hence, we performed coupled immunopre-
cipitation/immunoblot analyses and found that mdm2
levels were increased approximately 1.8-fold in E7-ex-
pressing cells compared to control cells (Fig. 2A, top).
This is a less dramatic increase than previously reported
in other cell systems (Thomas and Laimins, 1998; Seavey
et al., 1999). Since a previous study reported that E7
could interfere with the interaction of mdm2 and p53
(Seavey et al., 1999), we also determined the amount of
p53 bound to mdm2 by coimmunoprecipitation experi-
ments. Approximately 2.5-fold more p53 was coimmuno-
precipitated with mdm2 in E7-expressing cells, which
parallels the increase of mdm2 (1.8-fold) in these cells
(Fig. 2A). These results suggest that mdm2 is effectively
bound to p53 in E7-expressing IMR90 cells.
To determine whether the transcriptional activity of the
mdm2 promoter is increased in E7-expressing cells a
luciferase reporter plasmid under the control of the p53-
responsive element of the human mdm2 P2 promoter
was transfected into control and E7-expressing IMR90
cells. Similar to the synthetic p53-responsive reporter
construct (Fig. 1C), the expression of the mdm2 reporter
plasmid was decreased in E7-expressing cells to a level
that was approximately 40% of that of control cells (Fig.
2B). These experiments further support the notion that
E7-mediated p53 stabilization does not lead to a con-
comitant increase of transcriptional activity.
The recently described mdm2 homologue, mdmX, was
reported to bind and stabilize p53 by protecting it from
mdm2-mediated degradation (Jackson and Berberich,
2000). Interestingly, mdmX-bound p53 is transcriptionally
inert (Shvarts et al., 1997). Furthermore, mdmX can bind
and stabilize mdm2 and inhibit its ability to degrade p53
(Sharp et al., 1999). Hence mdmX appeared to be an
attractive candidate to mediate the effects of E7 on p53.
Analysis of mdmX protein levels in E7-expressing cells
has not been conclusive due to limitations of the existing
antibodies. Northern blot analyses revealed a slight, 1.4-
fold increase of mdmX mRNA in E7-expressing cells (Fig.
2C). Hence it is possible that mdmX may be involved in
p53 stabilization in E7-expressing cells.
Wild-type conformation of p53 in HPV-16 E7-
expressing IMR90 cells
To investigate whether the stabilized p53 in E7-ex-
pressing cells is in a mutant conformation we performed
immunoprecipitation experiments with conformation-
specific antibodies. The antibody PAb1620 preferentially
recognizes wild-type conformation p53 and the antibody
PAb240 preferentially detects p53 with a mutant confor-
mation (Gannon et al., 1990). HaCaT cells, which carry a
p53 with a mutant conformation (Lehman et al., 1993),
and C33A cells, which carry a p53 with a point mutation
at codon 273 (Scheffner et al., 1991) that has a wild-type
conformation (Medcalf and Milner, 1993), were used as
controls. Since these are mutant forms of p53 they do not
exactly comigrate with the wild-type p53 in IMR90 cells.
Precipitation with the wild-type conformation-specific
PAb1620 but not with mutant conformation-specific
PAb240 yielded a detectable signal in E7-expressing
cells (Fig. 3A). These results suggest that the majority of
p53 in E7-expressing cells is retained in a wild-type
conformation.
To corroborate this result we next determined whether
the stabilized p53 in E7-expressing cells is bound to
hsp90. Hsp90 can bind to p53 that is in a mutant con-
formation and stabilize it by preventing proteasome-me-
diated degradation (Blagosklonny et al., 1996). Geldana-
mycin is a drug that disrupts the interaction of mutant
conformation p53 with hsp90 and renders is susceptible
for proteasomal degradation (Blagosklonny et al., 1996;
Nagata et al., 1999; Whitesell et al., 1997). Control and
E7-expressing cells were treated with geldanamycin and
p53 steady state levels were determined by immunoblot-
ting. The breast cancer cell line SK-Br-3 contains hsp90-
bound p53 and was used as a positive control (Whitesell
FIG. 2. Expression of mdm2 and the mdm2 homologue mdmX in
control (LX) and HPV-16 E7 expressing (E7) IMR90 cells. (A) p53 is in
complex with mdm2 in E7-expressing cells. Equal amounts of protein
lysates were immunoprecipitated with mdm2-specific antibodies fol-
lowed by immunoblot analysis for mdm2 (top) and coprecipitated p53
(bottom). Quantitation of the signals is shown below the panels. (B)
Activity of the p53-responsive P2 promoter of human mdm2. Cells were
transfected with the corresponding firefly luciferase reporter construct.
Activity values were normalized for expression of a nonresponsive
renilla luciferase reporter. Values represent averages and standard
deviations of an experiment performed in triplicate. (C) Northern blot
analysis of mdmX RNA expression. Relative levels of mdmX mRNA are
shown below the top panel and have been corrected for equal loading
as determined by actin mRNA.
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et al., 1997). The p53 levels remained unchanged in
control and E7-expressing cells upon geldanamycin
treatment, while the p53 level in the SK-Br-3 cells de-
creased (Fig. 3B). These results suggest that the stabi-
lized p53 in E7-expressing cells is not complexed to
hsp90. Taken together these results indicate that the
stabilized p53 in E7-expressing cells is in a wild-type
conformation.
The stabilized p53 in HPV-16 E7-expressing cells is
localized to the nucleus
p53 signaling can be inhibited by mechanisms other
than mutations or conformational alterations. One such
mechanism involves aberrant subcellular localization.
We determined whether expression of E7 alters the sub-
cellular localization of p53. Nuclear and cytoplasmic frac-
tions were prepared from control and E7-expressing
cells and subjected to SDS–PAGE and p53 immunoblot
analysis. IB is an exclusively cytoplasmic protein and
was used as a marker. Some p53 was detected in the
cytoplasmic fractions in both control and E7-expressing
cells, but the ratio between cytoplasmic and nuclear p53
was similar in both cell populations (Fig. 4A). Hence, the
subcellular localization of p53 is not altered in E7-ex-
pressing cells.
Expression of E7 does not block nuclear export or
proteasomal degradation of p53 per se
The finding that the stabilized p53 is mainly nuclear in
E7-expressing cells led us to investigate whether E7
might block nuclear export of p53, which might result in
its stabilization. Control and E7-expressing IMR90 cells
were treated with the nuclear export inhibitor leptomycin
B (LMB) and p53 steady state levels were determined by
FIG. 3. The stabilized p53 in E7-expressing cells is in a wild-type conformation. (A) Immunoprecipitations with p53 antibodies PAb1620 and PAb240
were performed with lysates of control (LX) and HPV-16 E7-expressing (E7) IMR90 cells (1 mg) and HaCaT and C33A (C33) cells (500 g) followed
by p53 immunoblot analysis. PAb1620 preferentially recognizes wild-type conformation p53, whereas PAb240 preferentially precipitates mutant
conformation p53. Samples containing 100 g total protein were used as controls for direct Western blots. Background bands specific to each of the
antibodies used were detected in the “No lysate” control lanes and are indicated by an asterisk; immunoprecipitated p53 is indicated by arrows. (B)
Control (LX) and HPV-16 E7-expressing (E7) IMR90 cells were treated with geldanamycin, a compound that disrupts complexes of mutant p53 and
hsp90 and renders p53 susceptible to proteasomal degradation. SK-Br-3 cells contain hsp90-bound mutant p53 and were used as a positive control.
Levels of p53 were determined by immunoblot analysis normalized for GAPDH levels and are shown below the top panel.
FIG. 4. p53 is nuclear in control (LX) and HPV-16 E7-expressing (E7)
IMR90 cells and its nuclear export or proteasomal degradation is not
generally impaired. (A) Nuclear (N) and cytoplasmic (C) fractions were
subjected to p53 immunoblot analysis. IB was used as a cytoplasmic
marker. The ratio of cytoplasmic to nuclear p53 (C/N ratio) is indicated.
(B) Cells were treated for 4 h with 40 M lactacystin (LC, a proteasome
inhibitor) or for 8 h with 40 ng/ml leptomycin B (LMB, a nuclear export
inhibitor) and p53 levels were determined by immunoblot analyses.
Treatment with a radiomimetic dose (2.5 nM) of actinomycin (Act D) for
24 h was used as a positive control. GAPDH is shown to document
equal loading.
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immunoblotting. p53 steady state levels increased to a
similar extent in control and E7-expressing cells (Fig.
4B). This result indicates that E7 expression does not
block the nuclear export of p53. Since it has been re-
ported that E7 can interact with the S4 subunit of the 26S
proteasome (Berezutskaya and Bagchi, 1997) we deter-
mined whether E7 might stabilize p53 by generally inter-
fering with the proteasomal degradation machinery. Con-
trol and E7-expressing IMR90 cells were treated with the
proteasome inhibitor lactacystin. Similar increases in
p53 steady state levels were observed in control and
E7-expressing cells, indicating that E7 does not gener-
ally interfere with the proteasomal degradation machin-
ery (Fig. 4B). Treatment with the DNA-damaging agent
actinomycin D, which results in p53 stabilization in both
control and E7-expressing cells (Demers et al., 1994a;
Slebos et al., 1994), was used as a control in these
experiments (Fig. 4B).
Stabilized p53 in E7-expressing cells is susceptible to
degradation by exogenous mdm2
To determine whether E7 can protect p53 from degra-
dation by exogenous mdm2, mdm2 was transiently ex-
pressed in stable E7-expressing IMR90 cells and
changes in p53 levels were determined by immunofluo-
rescence. Transfection of HPV-16 E6, which induces
E6AP-mediated p53 degradation, was used as a positive
control. The DS-red plasmid encodes a fluorescent pro-
tein and was used as a transfection marker for these
experiments. Like E6, expression of mdm2 decreased
p53 levels in stable E7-expressing cells (Fig. 5). This
indicates that E7-stabilized p53 is still susceptible to
degradation by exogenous mdm2.
Exogenous p53 is transcriptionally active in E7-
expressing cells
To investigate whether E7 can interfere with the tran-
scriptional activity of exogenous p53 we transiently
transfected control and E7-expressing IMR90 cells with
increasing amounts of p53 and the p53-responsive lucif-
erase reporter plasmid pRGC-luc and determined its
transcriptional activity by using luciferase assays. In
agreement with our previous results (Fig. 1C) transcrip-
tional activity of endogenous p53 is diminished by ap-
proximately 60% in E7-expressing cells compared to the
control population. Exogenous p53, however, was able to
efficiently activate reporter gene expression in E7-ex-
pressing cells to a similar level as in control cells. This
indicates that in IMR90 cells, E7 does not impair the
transcriptional activity of exogenous p53.
DISCUSSION
The tumor suppressor protein p53 has a short half-life
in normal cells. Its half-life is determined by mdm2-
mediated proteasomal degradation (Honda et al., 1997).
The ubiquitin ligase (E3) mdm2 is a transcriptional target
of p53 and is thought to play a role as a feedback
regulator to keep p53 activity in check (Wu et al., 1993).
E7-expressing keratinocytes or fibroblasts contain in-
creased p53 levels (Demers et al., 1994b; Jones et al.,
1997b; Thomas and Laimins, 1998). Upregulation of p53
is an important component of the cellular response to
oncogenic insults that can culminate in cellular growth
arrest or apoptosis (reviewed in Levine, 1997). It is
thought that the ability of the high-risk HPV E6 proteins to
inactivate p53 by targeting it for proteasomal degrada-
tion (Scheffner et al., 1990) is to negate this cellular
reaction. Consistent with this model, a mutational anal-
ysis revealed that the ability of HPV-16 E7 to stabilize p53
correlates with cellular transformation and pRB degrada-
tion (Jones et al., 1997b). Other oncoproteins including
SV40 large tumor antigen (SV40 Tag) (Tiemann and Dep-
pert, 1994), adenovirus E1A (Ad E1A) (Lowe and Ruley,
1993), and c-myc (Hermeking and Eick, 1994) can each
stabilize p53. Since each of these oncoproteins results in
dysregulating the G1/S transition it is plausible that ab-
errant activation of the pRB-regulated transcription factor
E2F may cause p53 stabilization. One potential mecha-
nistic link between E2F activation and p53 stabilization
was suggested by the finding that p14ARF, an inhibitor of
mdm2-mediated p53 degradation (Zhang et al., 1998),
was E2F responsive (Bates et al., 1998), and its cellular
levels increased in response to Ad E1A and c-myc ex-
pression (de Stanchina et al., 1998; Zindy et al., 1998).
Surprisingly, however, p14ARF levels do not rapidly in-
crease upon HPV-16 E7 expression, and E7-mediated
p53 stabilization was observed in p19ARF-deficient mouse
embryo fibroblasts (Seavey et al., 1999). Hence other
pathways must exist that can interfere with the ability of
mdm2 to ubiquitinate p53 or the process of proteasomal
p53 degradation. As a first step toward the identification
of the biochemical pathways that may contribute to p53
stabilization in E7-expressing cells we analyzed p53 in
E7-expressing cells on a biochemical and cell biological
level. Our studies revealed no major differences between
short-lived p53 in normal cells and stabilized p53 in
HPV-16 E7-expressing IMR90 cells.
It has been reported that wild-type p53 can be func-
tionally inactivated by nuclear exclusion. This has been
documented in different carcinomas (Moll et al., 1992,
1995; Bosari et al., 1995; Ueda et al., 1995; Schlamp et al.,
1997), and in addition, some viral oncoproteins such as
the Ad E1B-55 kDa protein and the hepatitis B virus X
protein can mislocalize p53 to the cytoplasm, thereby
inhibiting its transcriptional activities (van den Heuvel et
al., 1993; Elmore et al., 1997). Subcellular fractionation
studies showed that p53 in E7-expressing cells remains
nuclear (Figs. 4A and 5) and immunoprecipitation studies
with conformation-specific antibodies (Fig. 3A) as well as
treatment with geldanamycin (Fig. 3B) demonstrated that
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the stabilized p53 in E7-expressing cells remains in a
wild-type conformation. An analysis of the phosphoryla-
tion state of p53 by two-dimensional gel electrophoresis
displayed no major differences in the number of phos-
pho-forms in control or E7-expressing cells (Fig. 1E).
In contrast to another study (Seavey et al., 1999), our
analyses revealed no evidence for a disruption of the
mdm2/p53 interaction in normal or E7-expressing cells
(Fig. 2A), suggesting that the interaction of mdm2 and
p53 is not generally decreased in E7-expressing cells.
The two studies were performed with different strains of
diploid normal human fibroblasts and it is of note that in
the IMR90 cells used in this study, we did not observe a
dramatic upregulation of mdm2 expression (Figs. 1B and
2A), suggesting that either there are differences in the
expression levels of E7 in the two studies or there may
be differences in the susceptibility to p53 activation be-
tween these strains of human fibroblasts.
Interestingly, however, our experiments revealed that
the stabilized p53 in E7-expressing cells remains sus-
ceptible to proteasomal degradation by exogenous
mdm2 as well as by the HPV-16 E6/E6-AP complex (Fig.
5). These results further support the notion that the sta-
bilized p53 in these cells is in a wild-type conformation
and is not inherently resistant to proteasomal degrada-
tion.
In addition, treatment of E7-expressing cells with the
nuclear export inhibitor leptomycin B led to a further
increase in cellular p53 levels, demonstrating that nu-
clear export of p53 is not generally abrogated in E7-
expressing cells (Fig. 4B). Similar results were obtained
when cells were treated with the proteasome inhibitor
lactacystin, suggesting that proteasomal p53 degrada-
tion is not completely blocked in E7-expressing cells
(Fig. 4B).
Additional studies will be necessary to delineate
whether E7 interferes with mdm2-mediated ubiquitina-
tion of p53 or whether E7 affects the turnover of ubiqui-
tinated p53. Interestingly, mdmX, a cellular homologue of
mdm2 that may act as dominant negative inhibitor of
mdm2, has been described. MdmX can bind p53 and
stabilize it by preventing mdm2-mediated degradation
FIG. 5. Stabilized p53 in HPV-16 E7-expressing cells remains susceptible to degradation by exogenous mdm2. HPV-16 E7-expressing IMR90 cells
were transiently transfected with mdm2 or HPV-16 E6 as a positive control. Untransfected E7-expressing IMR90 cells (U) are shown as controls. The
fluorescent protein DS-red was cotransfected to allow specific identification of the transfected cells. p53 was detected by immunofluorescence.
Nuclei were visualized by Hoechst staining.
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through the proteasome (Jackson and Berberich, 2000;
Sharp et al., 1999). MdmX-bound p53 was reported to be
transcriptionally inactive (Shvarts et al., 1997), which
made it an attractive candidate. Our preliminary analyses
revealed a 1.4-fold increase in mdmX mRNA levels in
E7-expressing cells (Fig. 2C), but due to antibody limita-
tions we could not determine whether mdmX or a related
protein may be present at higher levels in E7-expressing
cells and may contribute to p53 stabilization in E7-ex-
pressing IMR90 cells. Alternatively, E7 may interfere with
a step that involves recognition of ubiquitinated forms of
p53 by the proteasome. This process has not yet been
studied in great detail; however, it has been postulated
that ubiquitin-binding proteins such as hPLIC that are
associated with the proteasome may play a role in this
process (Kleijnen et al., 2000).
In normal cells, stabilization of p53 is generally ob-
served in response to genotoxic insults. Under these
conditions, p53 stabilization leads to a corresponding
increase of its transcriptional activation potential and
transcriptional induction of downstream target genes
(reviewed in Meek, 1999). Many of these genes encode
growth suppressive and cytotoxic proteins, and activa-
tion of p53 generally leads to growth arrest or apoptosis
(reviewed in Levine, 1997). In contrast, E7-expressing
IMR90 cells grow rapidly and the rate of spontaneous
apoptosis is similar to that in control cells. Our previous
work has indicated that expression of E7, while it mimics
a p53-dependent DNA damage response, does not fully
activate p53 (Jones et al., 1999). Most dramatically,
p21CIP1/waf1 protein levels but not mRNA levels are in-
creased in E7-expressing cells (see Figs. 1B and 1D),
consistent with an effect on protein stabilization rather
than p53-dependent transcriptional induction (Jones et
al., 1999). Hence we analyzed in more detail whether the
stabilized p53 in E7-expressing cells is activated as a
transcription factor. Transcriptional profiling of matched
control and E7-expressing cells showed no marked in-
creases in the mRNA levels of any of the known p53-
responsive genes present on this array (Fig. 1B). Simi-
larly, immunoblot analyses showed that levels of the
pro-apoptotic p53 targets bax (Miyashita and Reed, 1995)
and DR5 (alias TRAIL-R2/Apo2/Killer) (Wu et al., 1997)
were not increased in rapidly growing E7-expressing
IMR90 cells (Fig. 1D). Consistent with these findings,
analysis of the transcriptional activity of an artificial p53-
responsive reporter construct in a matched pair of con-
trol and E7-expressing IMR90 cells suggested that, de-
spite the higher steady state levels (Figs. 1A and 1D), the
transcriptional activity of p53 was decreased in E7-ex-
pressing cells (Figs. 1C, 2B, and 6). In particular, our
analysis did not reveal any evidence for increased mdm2
RNA expression in E7-expressing cells (Fig. 1B), as sug-
gested by a previous study that reported increased tran-
scription from the p53-responsive mdm2 promoter P2 in
E7-expressing cells (Seavey et al., 1999). Consistent with
this, mdm2 protein levels were only slightly increased in
E7-expressing cells (Fig. 2A). Hence we measured the
transcriptional activity of an mdm2 P2 promoter-driven
reporter construct in a matched pair of control and E7-
expressing IMR90 cells. Consistent with the results ob-
tained with the artificial p53-responsive reporter (Fig.
1C), we did not detect increased activity of this reporter
in E7-expressing cells; in fact, the transcriptional activity
of the mdm2 P2 promoter construct was decreased in
E7-expressing cells (Fig. 2B).
The decreased activity of the p53-responsive lucif-
erase reporters (Figs. 1C and 2B) appears at variance
with the unchanged levels of p53 target genes as deter-
mined by transcriptional profiling (Fig. 1B) and may sug-
gest that other transcriptional elements are also involved
in regulating the expression of these genes. Regardless,
our results demonstrate that expression of E7 results in
stabilization but not activation of p53.
Hence it is possible that the different mechanisms that
lead to p53 stabilization in E7-expressing cells and dur-
ing DNA damage are fundamentally different and that
additional modifications such as phosphorylation and/or
acetylation events are necessary to trigger transcrip-
tional activation of p53. Alternatively, E7 may interfere
with the transcriptional activation of p53. This has been
suggested by earlier studies demonstrating that expres-
sion of E7 could interfere with p53-dependent activation
of reporter plasmids in transient assays. These experi-
ments suggested that the ability of E7 to interfere with
p53-mediated transcriptional activation might be corre-
lated with the capacity of E7 to interact with TATA-box-
binding protein, TBP (Massimi and Banks, 1997). Addi-
tional studies will be necessary to further address these
issues. To address whether E7 could also interfere with
transcriptional activity of exogenous p53, we performed
reporter assays with increasing amounts of exogenous
p53 in a matched pair of control and E7-expressing
FIG. 6. Transcriptional activity of exogenous p53 in control (LX) and
HPV-16 E7-expressing (E7) IMR90 populations. Cells were cotrans-
fected with 500 ng of the p53-responsive firefly luciferase reporter
pRGC-luc and the indicated amounts of p53. Activity values were
normalized for expression of a nonresponsive renilla luciferase re-
porter. Values represent averages and standard deviations of an ex-
periment performed in triplicate.
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IMR90 cells using an artificial p53-responsive reporter.
These studies showed that exogenous p53 is transcrip-
tionally active in E7-expressing cells (Fig. 6).
It is remarkable that many viruses have developed
multiple strategies to interfere with the activities of p53.
This has been best demonstrated in the case of adeno-
viruses that encode multiple proteins that impinge on
p53 functions. The Ad E1A protein can stabilize p53
through a mechanism that involves E2F-dependent acti-
vation of p14ARF (de Stanchina et al., 1998; Bates et al.,
1998). The Ad E1B protein can inactivate p53 by binding
directly to its transcriptional activation domain (Sarnow
et al., 1982; Kao et al., 1990; Yew et al., 1994). In addition
the E4orf6 protein can enhance the destabilization of p53
through its interaction with E1B-55 kDa. Both E4orf6 and
E1B-55 kDa bind independently to p53 without inducing
its degradation. Concomitant expression of the two on-
cogenes leads to rapid turnover of p53 (Querido et al.,
1997; Steegenga et al., 1998). In contrast, E4orf3 can
relieve the inhibition of p53 activity by Ad E1B (Konig et
al., 1999). Hence it is not surprising that high-risk HPVs
encode multiple proteins that impinge on p53 function.
HPV-16 E7 expression leads to p53 stabilization, but the
stabilized p53 is retained in a transcriptionally impotent
state. In concert with the ubiquitin ligase E6-AP, the
HPV-16 E6 protein can interact with p53 and target it for
proteasomal degradation (Scheffner et al., 1993, 1995). It
has recently been reported that mdm2-mediated p53
degradation is also abrogated in HPV-positive cervical
cancer cells and critically depends on E6/E6-AP (Heng-
stermann et al., 2001). Given our results and the fact that
the only other viral protein consistently expressed in
cervical cancer cells is HPV E7 it is thus conceivable that
E7 is responsible for blocking mdm2-mediated p53 deg-
radation in these cells.
MATERIALS AND METHODS
Cell lines, retroviral infection, and transfection
Low-passage normal human diploid lung fibroblasts
(IMR90), the keratinocyte cell line HaCaT, the HPV-neg-
ative cervical cancer cell line C33A, and the breast can-
cer cell line SK-Br-3 were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 50 U/ml penicillin, and 50
g/ml streptomycin.
Recombinant retroviruses LXSN and LXSN-HPV-16 E7
were obtained from D. Galloway and used for retroviral
transduction of IMR90 cells. Cells were incubated for 4 h
with virus-containing supernatant in the presence of 4
g/ml hexadimethrine bromide (polybrene) (Sigma).
Pooled stable cell populations were obtained by selec-
tion with 300 g/ml G418 (Gemini Bio-Products) for 8
days.
Transient transfection of IMR90 cell populations were
performed by incubating the cells in 6-well plates for 4 h
at 37°C in 1 ml Opti MEM I (Gibco) containing 4 g DNA
and 10 g/ml polybrene followed by incubation with 24%
DMSO (ICN Biomedicals Inc.) in Opti MEM I for 4 min at
room temperature. The cells were washed three times
with PBS, supplemented with DMEM with 10% FBS, and
processed 24 h posttransfection.
RNA isolation, cDNA arrays, and Northern blotting
Total RNA was isolated using the RNeasy kit (Qiagen)
according to the manufacturer’s recommendations, fol-
lowed by treatment with 1 U/l DNase I (Roche) for 1 h
at 37°C. To test for DNA contamination, RNA samples
were subjected to PCR analysis using GAPDH primers.
mRNA was isolated from total RNA by using the OligoTex
kit (Qiagen) according to the manufacturer’s manual and
used as a template to prepare a 32P-labeled single-
stranded cDNA hybridization probe. A Human Apoptosis
ATLAS cDNA array (Clontech) was used. The signals
were visualized with a STORM PhosphoImager and the
results were quantitated using ATLAS Image 1.5 software
(Clontech). For Northern blot analyses 10 g total RNA
was separated on a 1% formaldehyde/agarose gel, trans-
ferred to a NYTRAN SuPerCharge nylon membrane
(Schleicher & Schuell), and crosslinked with a Strata-
linker (Stratagene). The cDNA probes were 32P-labeled
using the STRIP-EZ DNA kit (Ambion) following the man-
ufacturer’s instructions and hybridized in ExpressHyb
(Clontech) according to the manufacturer’s manual. The
signals were visualized with a STORM PhosphoImager
and quantitated using ImageQuant software.
Immunological methods
For immunoblot analyses cells were lysed in 1% NP-40
buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1% Nonidet-
P-40, 0.01% PMSF, 1 g/ml aprotinin, 1 g/ml leupeptin),
immediately scraped off the plates, incubated on ice for
20 min, and centrifuged for 10 min at 4°C at 16,000g in a
microcentrifuge. Protein concentrations of the lysates
were determined by the Bradford method (Bio-Rad). Sam-
ples containing 100 g of protein were separated by
SDS–PAGE and transferred to a PVDF membrane (Immo-
bilion P, Millipore). Antibody complexes were detected by
enhanced chemiluminescence (Renaissance Enhanced
Luminol Reagent, NEN Life Science Products). Primary
antibodies were used at the following dilutions: p53
(Ab-6, 1:1000, Calbiochem), p21CIP1/waf1 (Ab-1, 1:1000, Cal-
biochem), bax (1:500, Pharmingen), -actin (1:10,000,
CHEMICON), GAPDH (1:600, CHEMICON), E7 (mixture of
8C9, 1:100, Zymed and ED17, 1:1000, Santa Cruz), mdm2
(N-20, 1:300, Santa Cruz), DR5 (1:500, IMGENEX), IB
(1:200, Santa Cruz). Secondary HRP-conjugated antibod-
ies were used at 1:10,000 dilutions (Amersham). ECL
images were acquired using a Fluoro-S MultiImage MAX
(Bio-Rad) with a supercooled digital camera (Nikon) and
quantitated using QuantityOne software (Bio-Rad). Equal
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loading was controlled using GAPDH or -actin immu-
noblots.
For immunoprecipitations cells were lysed and pro-
cessed as described above. Samples containing 0.5–1
mg total protein were incubated for 1.5 h at 4°C with 2 g
of specific antibody, followed by protein A–Sepharose
beads (Pharmacia) or protein G PLUS-agarose beads
(Santa Cruz) for 1 h at 4°C at constant rotation. The p53
antibodies used were PAb1620 (Calbiochem) and
PAb240 (Calbiochem), and for mdm2 Ab-1 (Calbiochem)
was used. Immunocomplexes were washed four to six
times in 1% NP-40 lysis buffer and subjected to SDS–
PAGE and immunoblot analysis. An anti-mouse  light-
chain-specific secondary antibody (1:10,000, Southern
Biotechnology Associates) was used to facilitate detec-
tion of immunoprecipitated p53.
For half-life determinations, control and E7-expressing
IMR90 cells were treated with 30 g/ml of the translation
inhibitor cycloheximide (Sigma) for the indicated time
periods. The cells were lysed and the p53 steady state
levels were determined by immunoblot analysis. Images
were digitally acquired using a Bio-Rad Fluoro-S-Max
Multi-imager and quantitated using the manufacturer’s
software. The levels of p53 were normalized for -actin
expression.
For immunofluorescence analyses the cells were tran-
siently transfected as described above. After 36 h the
cells were fixed in 2% paraformaldehyde for 30 min at
25°C, washed in PBS, permeabilized with 100% methanol
for 10 min at20°C, and washed with PBS. After that the
cells were incubated with 2.5% donkey serum in PBS for
5 min at 37°C, washed with PBS, incubated with primary
antibody (p53, Ab-6, Calbiochem, 1:100) for 1 h at 37°C,
and washed twice in PBS followed by an incubation with
the FITC-coupled secondary donkey anti-mouse anti-
body (1:200) for 1 h at 37°C. The nuclei were stained with
Hoechst (1:2000 in H2O).
Drug treatments
Geldanamycin (Sigma) was dissolved in DMSO at a
concentration of 1.5 mM. IMR90 control and E7-express-
ing cells and SK-Br-3 cells were treated for 4 h with 1.5
M geldanamycin or mock-treated with an equal volume
of DMSO. Leptomycin B (Sigma) was dissolved in etha-
nol at a concentration of 10 g/ml. IMR90 control and
E7-expressing cells were treated for 8 h with 40 ng/ml
leptomycin B. Lactacystin (BIOMOL) was dissolved in
water at a concentration of 40 mM. IMR90 control and
E7-expressing cells were treated for 4 h with 40 M
lactacystin. Actinomycin D (Sigma) was dissolved in eth-
anol at a concentration of 2.5 M. IMR90 control and
E7-expressing cells were treated for 24 h with 2.5 nM
actinomycin D.
Luciferase assays
Stable control and E7-expressing human diploid lung
fibroblasts (IMR90) were transfected in 6-well plates with
500 ng of firefly luciferase reporter plasmid either under
the control of an artificial p53-responsive promoter car-
rying 17 tandem repeats of the p53 consensus DNA-
binding sequence derived from the ribosomal gene clus-
ter (Kern et al., 1991) (pRGC-luc) or under the control of
the p53-responsive human mdm2 promoter (pGL2-
mdm2-luc) (Zauberman et al., 1995) (kind gifts from M.
Oren). Twenty nanograms of the noninducible renilla
luciferase reporter plasmid (pRL-TK) was cotransfected
as a transfection control. The cells were lysed after 24 h
in 30 l lysis buffer (Dual-Luciferase Reporter Kit, Pro-
mega) per well, scraped off the plate, and centrifuged for
10 min at 4°C at 16,000g. The supernatants were sub-
jected to the dual luciferase assay and the firefly lucif-
erase activity was normalized for renilla luciferase ex-
pression.
Subcellular fractionation
Stable control and E7-expressing IMR90 cells were
washed in PBS and scraped in sucrose buffer (250 mM
sucrose, 10 mM MOPS, pH 7.2, 1 mM EDTA, 0.01% PMSF,
1 g/ml aprotinin, 1 g/ml leupeptin). The cells were
then homogenized by 30 strokes of a Teflon tissue ho-
mogenizer (Glas-Col, Terre Haute, IN). Nuclei were pel-
leted at 700g at 4°C for 10 min. The supernatant is the
cytoplasmic protein fraction. The pellet was resus-
pended in 1% NP-40 buffer and the nuclear lysate was
cleared by centrifugation for 10 min at 4°C at 16,000g.
Equal amounts of protein from the cytoplasmic and nu-
clear fraction were separated by SDS–PAGE and p53
levels were determined by immunoblotting.
Two-dimensional gel electrophoresis
For two-dimensional gel analyses of endogenous p53
(Stewart et al., 2001), 1 mg of protein lysate from LXSN
cells or 250 g of protein lysate from E7 cells was
prepared in a final volume of 600 l of IEF sample buffer
[9.5 M urea (Pharmacia), 2% NP-40, 2% -mercaptoetha-
nol, 0.2% ampholytes, pH 5–8 (Pharmacia), 0.001% bro-
mophenol blue]. A truncated form of recombinant human
p53 (amino acids 1–353) was incubated in each sample
as an internal standard to permit alignment of p53 phos-
pho-forms; the truncated human p53 was prepared as
previously described (Szak and Pietenpol, 1999). IEF was
performed using the PROTEAN IEF system (Bio-Rad) and
17-cm isoelectric strip gels, pH 5–8 (Bio-Rad). The iso-
electric gels were passively rehydrated for 10 h in IEF
sample buffer containing the protein lysate prior to fo-
cusing for 60,000 V-h. After IEF, gels were incubated for
15 min in equilibration buffer I [6 M urea, 2% SDS, 0.375
M Tris (pH 8.8), 20% glycerol, 130 mM DTT] and 15 min in
83IMPAIRMENT OF p53 BY HPV-16 E7 ONCOPROTEIN
equilibration buffer II [6 M urea, 2% SDS, 0.375 M Tris (pH
8.8), 20% glycerol, 135 mM iodoacetamide (Sigma)] prior
to separation by SDS–PAGE. Detection of p53 was by
immunoblot using PAb1801 (1 g/ml; Calbiochem).
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